Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: A pilot study

Cell Biochemistry and Function

Volumn 27, Issue 2, 2009, Pages 81-87

  Tanriverdi Akhisaroglu, Serpil ^a   Menderes, A ^a   Oktay, G ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Collagen; Keloid; Matrix metalloproteinase; MMP 2; MMP 9; Scars

Indexed keywords

GELATINASE A; GELATINASE B; COLLAGEN; ENZYME PRECURSOR; GELATINASE; PROGELATINASE;

ADULT; ARTICLE; ATROPHIC SKIN DISEASE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTROPHIC SCAR; KELOID; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCAR FORMATION; SKIN BIOPSY; ZYMOGRAPHY; ADOLESCENT; CHEMISTRY; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN;

ADOLESCENT; ADULT; CICATRIX, HYPERTROPHIC; COLLAGEN; ENZYME PRECURSORS; FEMALE; GELATINASES; HUMANS; KELOID; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PILOT PROJECTS; SKIN; YOUNG ADULT;

EID: 63149142772     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1537     Document Type: Article

References (35)

1. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998; 4(1): 19-24.
2. Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg 2006; 8(6): 362-368.
3. Alster TS, Tanzi EL. Hypertrophic scars and keloids: etiology and management. Am J Clin Dermatol 2003; 4(4): 235-243.
4. Atiyeh BS, Costagliola M, Hayek SN. Keloid or hypertrophic scar: the controversy: review of the literature. Ann Plast Surg 2005; 54(6): 676-680.
5. English RS, Shenefelt PD. Keloids and hypertrophic scars. Dermatol Surg 1999; 25(8): 631-638.
6. Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg 1999; 104(5): 1435-1458.
7. Goodman G. Post acne scarring: a review. J Cosmet Laser Ther 2003; 5(2): 77-95.
8. Madlener M, Parks WC,Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 1998; 242(1): 201-210.
9. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
10. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999; 274(31): 21491-21494.
11. Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen 1999; 7(6): 423-432.
12. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000; 14(17): 2123-2133.
13. Vihinen P, la-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5(3): 203-220.
14. Santos MC, Souza AP, Gerlach RF, Tabchoury CM, Line SR. Inhibition of human gelatinases (matrix metalloproteinase-2 and matrix metalloproteinase-9) activity by zinc oxide: a possible mechanism to enhance wound healing. Br J Dermatol 2001; 145(5): 854-855.
15. Gillard JA, Reed MW, Buttle D, Cross SS, Brown NJ. Matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 during human dermal wound healing. Wound Repair Regen 2004; 12(3): 295-304.
16. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92(8): 827-839.
17. Inkinen K, Turakainen H, Wolff H, Ravanti L, Kahari VM, Ahonen J. Expression and activity of matrix metalloproteinase-2 and -9 in experimental granulation tissue. APMIS 2000; 108(5): 318-328.
18. Agren MS. Gelatinase activity during wound healing. Br J Dermatol 1994; 131(5): 634-640.
19. Contractor SF, Sooranna SR. Gelatin degrading activity in early and term human placenta. J Dev Physiol 1981; 3(5): 305-308.
20. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193(1): 265-275.
21. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102(1): 196-202.
22. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29(3): 225-229.
23. Craig RD, Schofield JD, Jackson DS. Collagen biosynthesis in normal and hypertrophic scars and keloid as a function of the duration of the scar. Br J Surg 1975; 62(9): 741-744.
24. Akita S, Akino K, Yakabe A, et al. Combined surgical excision and radiation therapy for keloid treatment. J Craniofac Surg 2007; 18(5): 1164-1169.
25. Chipev CC, Simon M. Phenotypic differences between dermal fibroblasts from different body sites determine their responses to tension and TGFbeta1. BMC Dermatol 2002; 21(2): 13. Epub 21 Nov 2002.
26. Neely AN, Clendening CE, Gardner J, Greenhalgh DG, Warden GD. Gelatinase activity in keloids and hypertrophic scars. Wound Repair Regen 1999; 7(3): 166-171.
27. Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol 2001; 137(11): 1429-1434.
28. Le J, Dauchot P, Perrot JL, Cambazard F, Frey J, Chamson A. Quantitative zymography of matrix metalloproteinases by measuring hydroxyproline: application to gelatinases A and B. Electrophoresis 1999; 20(14): 2824-2829.
29. Sadick H, Herberger A, Riedel K, et al. TGF-beta1 antisense therapy modulates expression of matrix metalloproteinases in keloid-derived fibroblasts. Int J Mol Med 2008; 22(1): 55-60.
30. Fujiwara M, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br J Dermatol 2005; 153(2): 295-300.
31. Soo C, Shaw WW, Zhang X, Longaker MT, Howard EW, Ting K. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg 2000; 105(2): 638-647.
32. Bullen EC, Longaker MT, Updike DL, et al. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J Invest Dermatol 1995; 104(2): 236-240.
33. Manuel JA, Gawronska-Kozak B. Matrix metalloproteinase 9 (MMP-9) is upregulated during scarless wound healing in athymic nude mice. Matrix Biol 2006; 25(8): 505-514.
34. Dang CM, Beanes SR, Lee H, Zhang X, Soo C, Ting K. Scarless fetal wounds are associated with an increased matrix metalloproteinase-to-tissue-derived inhibitor of metalloproteinase ratio. Plast Reconstr Surg 2003; 111(7): 2273-2285.
35. Ala-aho R, Kahari VM. Collagenases in cancer. Biochimie 2005; 87(3-4): 273-286.